Immunodiagnostic Systems Holdings (IDH)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 14.1 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.72 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Mar | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Last ex-div: 5th Sep, paid: 28th Sep more... Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | +50.4% | |||||||||
FINANCIAL BRIEF: For the six months ended 30 September 2012, Immunodiagnostic Systems Hldgs PLC revenues decreased 13% to L23.8M. Net income decreased 28% to L4.7M. Revenues reflect Europe Direct segment decrease of 19% to L8.6M, USA Direct segment decrease of 13% to L9.9M. Net income also reflects Interest Income decrease of 5% to L108K (income). Basic Earnings per Share excluding Extraordinary Items decreased from L0.23 to L0.17. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Sep '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 1 | 1 | 4 |
Immunodiagnostic Systems Holdings plc (IDS) is engaged in manufacturing and distributing medical diagnostic products. The Company is also involved in research and development projects. The Company’s main operation is within the in vitro diagnostic (IVD) testing industry, supplying test kits to hospital and research laboratories. The Company is also engaged in the provision of immunoassay tests for the determination of vitamin D (both 25-Hydroxy and 1,25-Dihydroxy). The Company’s product include 1,25-Dihydroxy Vitamin D EIA, 1,25-Dihydroxy Vitamin D RIA, 25-Hydroxy Vitamin D EIA, 25-Hydroxy Vitamin D RIA ,Alpha CrossLaps (CTX-I) EIA, Automated IDS-iSYS System, BoneTRAP (TRAcP 5b) ELISA, Corticosterone EIA, Corticosterone HS EIA and CrossLaps for Culture (CTX-I) ELISA.
Directors: Patrik Dahlen (CEO) 51, Christopher Yates (Fin. Dir.) 38, Martha Garrity (Exec. Dir.) 51, Alain Rousseau (Exec. Dir.) 61, Barry Hextall (Other) ,
No. of Employees: 324 No. of Shareholders: n/a
| Last Annual | March 31st, 2012 |
| Last Interim | September 30th, 2012 |
| Shares in Issue | 28,336,915 |
| Free Float | 17.1m (60.4%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Boldon Business Park 10 Didcot Way, BOLDON, NE35 9PD, United Kingdom |
| Web | http://www.idsplc.com |
| Phone | +44 191 5190660 |
| Contact | Paul Hailes (Secy.) |
| Registrar | Computershare Services (London) |
| Auditors | Baker Tilly UK Audit LLP |
| 10th May | Holding(s) in Company |
| 9th May | Additional Listing |
| 2nd May | Entry into Chinese Diagnostics Market |
| 25th Apr | Trading Update - Replacement |
| 23rd Apr | Holding(s) in Company |
| 16th Apr | Holding(s) in Company |
Recent ↓
